Brenda Cooperstone – Biography
Last update: 3 days agoExecutive profile
Brenda was Senior Vice President and Chief Development Officer for rare disease in Global Product Development for Pfizer. Brenda Cooperstone joined Senti Biosciences in 2023.
Brenda Cooperstone is currentlyDirector at Lexeo Therapeutics - View - Lexeo Therapeutics org chart
Director at Senti Biosciences - View - Senti Biosciences org chart
Create your alert
to follow the career of Brenda Cooperstone.
Education
In 1988, Brenda Cooperstone completed a Doctor of Medicine at McGill University.
They have also studied at McGill University :
Find more alumni from McGill University
More about Brenda Cooperstone
Selected links
Do you need to know more about Brenda Cooperstone? More results.
Participate
Social media
- Brenda Cooperstone on Google News, X (Twitter), LinkedIn, YouTube
- View the pictures of Brenda Cooperstone
The colleagues of Brenda Cooperstone
Company Colleagues
- At Lexeo Therapeutics, Brenda Cooperstone has 25 colleagues including Nolan Townsend (CEO & Director), Mette Kirstine Agger (Director)…
- At Senti Biosciences, Brenda Cooperstone has 18 colleagues including Tim Lu (CEO & Director), Fran Schulz (Director)…
Industry Colleagues
- In the Biotechnology industry, Brenda Cooperstone has 35,756 colleagues in 2,406 companies located in 42 countries. 16,877 executive movements have been recorded in the last 12 months. Learn more about Biotechnology.
Report an error
Update the org chart details of Brenda Cooperstone.
Get in Touch
Here are a few tips for establishing great contacts.
and ask for Brenda Cooperstone.
